Tyrosine kinase receptors, the monoclonal antibodies (trastuzumab and pertuzumab) have been approved by the FDA (U.S. Food and Drug Administration) for the treatment of HER2 positive breast cancer patients. The gene discussed is ERBB2; the disease is breast cancer.